UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry

Orphanet journal of rare diseases, 2021-07, Vol.16 (1), p.294-294, Article 294

2021

Volltextzugriff (PDF)

Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study

BMC cardiovascular disorders, 2020-12, Vol.20 (1), p.504-10, Article 504

2020

Volltextzugriff (PDF)

Correction to: Elderly patients with atrial fibrillation in routine clinical practice: peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study

BMC cardiovascular disorders, 2021-02, Vol.21 (1), p.91-1, Article 91

2021

Volltextzugriff (PDF)

The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction

Journal of hypertension, 2001-06, Vol.19 Suplement 1 (1), p.S21-S32

2001

Volltextzugriff (PDF)

C0473: Prevention of Thromboembolic Events? European Registry in Venous Thromboembolism - Design of the Prefer in VTE

Thrombosis research, 2014-05, Vol.133, p.S122-S122

2014

Volltextzugriff (PDF)

C0472: Trends in Medical Management of Patients with VTE in 7 European Countries: First Baseline Data of the Prefer in VTE Registry

Thrombosis research, 2014-05, Vol.133, p.S121-S122

2014

Volltextzugriff (PDF)

Logistics of Monitoring of Vitamin K Antagonists in Western European Countries: Prefer in Vte Registry

Value in health, 2014-11, Vol.17 (7), p.A504-A504

2014

Volltextzugriff (PDF)

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR

The New England journal of medicine, 2021-12, Vol.385 (23), p.2150-2160

2021

Volltextzugriff (PDF)

P1.24: Dose-Dependent Inward Arterial Remodelling and de Stiffening after Olmesartan in Hypersentsives with Metabolic Syndrome: The Vascular Mechanism Study

Artery research, 2013, Vol.7 (3-4), p.116-117

2013

Volltextzugriff (PDF)

Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist

Journal of hypertension, 2001-06, Vol.19 Suplement 1 (1), p.S41-S48

2001

Volltextzugriff (PDF)

Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year follow-up of more than 13,000 patients from the ETNA-AF-Europe study

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Volltextzugriff (PDF)

Edoxaban in atrial fibrillation with PCI by ACS or stable CAD presentation: a pre-specified analysis of the ENTRUST-AF PCI trial

European heart journal, 2020-11, Vol.41 (Supplement_2)

2020

Volltextzugriff (PDF)

Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study

European heart journal. Cardiovascular pharmacotherapy, 2021-04, Vol.7 (Supplement_FI1), p.f30-f39

2021

Volltextzugriff (PDF)

PRO134 HEALTH-RELATED QUALITY OF LIFE IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT) PATIENTS IN EUROPE AND US: AN OBSERVATIONAL DISEASE REGISTRY

Value in health, 2019-11, Vol.22, p.S866-S866

2019

Volltextzugriff (PDF)

PCV181 - Logistics of Monitoring of Vitamin K Antagonists in Western European Countries: Prefer in Vte Registry

Value in health, 2014-11, Vol.17 (7), p.A504-A504

2014

Volltextzugriff (PDF)

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study

Thrombosis journal, 2018-05, Vol.16 (1), p.9-9, Article 9

2018

Volltextzugriff (PDF)

OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE (OM/HCTZ) 40/25MG PROVIDES GREATER AMBULATORY BLOOD PRESSURE-LOWERING VS OM/HCTZ 20/25MG IN ELDERLY AND SEVERE PATIENTS UNCONTROLLED BY OM: PP.5.203

Journal of hypertension, 2010-06, Vol.28, p.e109

2010

Volltextzugriff (PDF)

OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE (OM/HCTZ) 40/25MG PROVIDES GREATER AMBULATORY BLOOD PRESSURE-LOWERING VS OM/HCTZ 20/25MG IN MODERATE-TO-SEVERE PATIENTS UNCONTROLLED BY OM: PP.5.207

Journal of hypertension, 2010-06, Vol.28, p.e110

2010

Volltextzugriff (PDF)

ADDING HYDROCHLOROTHIAZIDE PROVIDES DOSE-DEPENDENT SEATED BLOOD PRESSURE REDUCTIONS IN PATIENTS WITH MODERATE-TO-SEVERE HYPERTENSION NOT CONTROLLED BY OLMESARTAN MEDOXOMIL 40MG: PP.5.205

Journal of hypertension, 2010-06, Vol.28, p.e109-e110

2010

Volltextzugriff (PDF)

ADDING HYDROCHLOROTHIAZIDE (HCTZ) PROVIDES DOSE-DEPENDENT AMBULATORY BLOOD PRESSURE (ABP) REDUCTIONS IN MODERATE-TO-SEVERE PATIENTS UNCONTROLLED BY OLMESARTAN MEDOXOMIL (OM) 40MG: PP.5.220

Journal of hypertension, 2010-06, Vol.28, p.e114-e115

2010

Volltextzugriff (PDF)

Dose-dependent inward arterial remodelling and de stiffening after olmesartan in hypersentsives with metabolic syndrome: The vascular mechanism study

Artery research, 2013-09, Vol.7 (3-4), p.116-117

2013

Volltextzugriff (PDF)

Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil

Journal of hypertension. Supplement, 2001-06, Vol.19 (1), p.S33-S40

2001

Volltextzugriff (PDF)

Dose-dependent inward arterial remodelling and de stiffening after olmesartan in hypersentsives with metabolic syndrome: The vascular mechanism study

Artery research, 2013, Vol.7 (3), p.116-117

2013

Volltextzugriff (PDF)

Clinical efficacy of olmesartan medoxomil

Journal of hypertension, 2003-05, Vol.21 Suppl 2 (2), p.S43-S46

2003

Volltextzugriff (PDF)

COMBINATION THERAPY OF OLMESARTAN MEDOXOMIL WITH AMLODIPINE OR ATENOLOL MAINTAINS STEADY STATE PHARMACOKINETICS OF EACH DRUG UNCHANGED: P2.329

Journal of hypertension, 2004-06, Vol.22 (Suppl. 2), p.S244

2004

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(42)

Sprache

Englisch
(35)
Deutsch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry

Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study

The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction

C0473: Prevention of Thromboembolic Events? European Registry in Venous Thromboembolism - Design of the Prefer in VTE

C0472: Trends in Medical Management of Patients with VTE in 7 European Countries: First Baseline Data of the Prefer in VTE Registry

Logistics of Monitoring of Vitamin K Antagonists in Western European Countries: Prefer in Vte Registry

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR

P1.24: Dose-Dependent Inward Arterial Remodelling and de Stiffening after Olmesartan in Hypersentsives with Metabolic Syndrome: The Vascular Mechanism Study

Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist

Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year follow-up of more than 13,000 patients from the ETNA-AF-Europe study

Edoxaban in atrial fibrillation with PCI by ACS or stable CAD presentation: a pre-specified analysis of the ENTRUST-AF PCI trial

Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study

PRO134 HEALTH-RELATED QUALITY OF LIFE IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT) PATIENTS IN EUROPE AND US: AN OBSERVATIONAL DISEASE REGISTRY

PCV181 - Logistics of Monitoring of Vitamin K Antagonists in Western European Countries: Prefer in Vte Registry

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study

OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE (OM/HCTZ) 40/25MG PROVIDES GREATER AMBULATORY BLOOD PRESSURE-LOWERING VS OM/HCTZ 20/25MG IN ELDERLY AND SEVERE PATIENTS UNCONTROLLED BY OM: PP.5.203

OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE (OM/HCTZ) 40/25MG PROVIDES GREATER AMBULATORY BLOOD PRESSURE-LOWERING VS OM/HCTZ 20/25MG IN MODERATE-TO-SEVERE PATIENTS UNCONTROLLED BY OM: PP.5.207

ADDING HYDROCHLOROTHIAZIDE PROVIDES DOSE-DEPENDENT SEATED BLOOD PRESSURE REDUCTIONS IN PATIENTS WITH MODERATE-TO-SEVERE HYPERTENSION NOT CONTROLLED BY OLMESARTAN MEDOXOMIL 40MG: PP.5.205

ADDING HYDROCHLOROTHIAZIDE (HCTZ) PROVIDES DOSE-DEPENDENT AMBULATORY BLOOD PRESSURE (ABP) REDUCTIONS IN MODERATE-TO-SEVERE PATIENTS UNCONTROLLED BY OLMESARTAN MEDOXOMIL (OM) 40MG: PP.5.220

Dose-dependent inward arterial remodelling and de stiffening after olmesartan in hypersentsives with metabolic syndrome: The vascular mechanism study

Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil

Dose-dependent inward arterial remodelling and de stiffening after olmesartan in hypersentsives with metabolic syndrome: The vascular mechanism study

Clinical efficacy of olmesartan medoxomil

COMBINATION THERAPY OF OLMESARTAN MEDOXOMIL WITH AMLODIPINE OR ATENOLOL MAINTAINS STEADY STATE PHARMACOKINETICS OF EACH DRUG UNCHANGED: P2.329

Suchergebnisse filtern